Nymox re-files urine test kit for Alzheimer's with FDA
This article was originally published in Clinica
In another attempt to gain US market approval for a test kit version of its urine test for Alzheimer's disease, Nymox Pharmaceutical has filed with the FDA an amendment to its previously rejected premarket approval (PMA) application for the product.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.